U.S. Opportunities Fund - Investor EUR Acc (VANGUOE)
Related Documents
NAV Price ()
—
Number of stocks
—
—
Risk Indicator
—
Start a savings plan or make a one-off investment
Invest now with an online broker
Learn moreAbout this fund
Fund objectives
- The Fund seeks to provide long-term capital growth.
- The Fund employs an “active management” strategy to invest mainly in U.S. stocks, with an emphasis on companies that are considered to have prospects for rapid earnings growth. The Fund’s Sub-Investment Manager, PRIMECAP Management Company (“PRIMECAP”), uses fundamental research to identify stocks that are expected to outperform the market over a three to five-year time horizon and that are available at attractive prices relative to their fundamental values. The Fund has the flexibility to invest in companies of any size, but it mostly invests in small and mid-cap stocks.
- The Fund may measure performance against the Russell 3000 Index (the “Index”), a market-capitalisation-weighted stock market index, composed of the top 3,000 US publically traded companies, as ranked by market capitalisation, or the total dollar value of all outstanding shares. The Fund is not otherwise constrained by or managed with reference to the Index. The Index does not define the investment universe of the Fund and the composition of the Fund may deviate significantly from that of the Index.
- The Fund’s policy is to remain substantially invested in common stocks that are listed or traded on exchanges or markets in the United States.
Fund facts
Share class inception
04 Dec 2006
Minimum initial investment
€100,000.00
Investment structure
Irish UCITS
Share Class Assets'
Total Assets
Strategy
Active
Asset Class
Equity
Domicile
Ireland
Dividend schedule
—
Legal entity
Vanguard Investment Series PLC
Tax status
Austria, Germany and Switzerland reporting
Benchmark
Russell 3000 Index
The value of investments, and the income from them, may fall or rise and investors may get back less than they invested.
Performance
Risk and Volatility
As at 28 Feb 2026
Beta
R²
Annualized Tracking Error
1 year
3 years
5 years
Please note Beta and R-squared data will only display for funds with 3 full years of history.
The value of investments, and the income from them, may fall or rise and investors may get back less than they invested.
Portfolio data
Characteristics
| Fundamentals | Fund | Benchmark | As at |
|---|---|---|---|
| Number of stocks | 220 | 2,936 | 28 Feb 2026 |
| Median market capital | 24.0 B | 215.8 B | 28 Feb 2026 |
| 29.8 x | 26.8 x | 28 Feb 2026 | |
| 4.1 x | 4.6 x | 28 Feb 2026 | |
| 12.3% | 24.4% | 28 Feb 2026 | |
| 16.4% | 22.4% | 28 Feb 2026 | |
| Portfolio turnover rate | 18.9% | — | 31 Dec 2025 |
Market allocation
As at 28 Feb 2026
| Country | Region | Fund | Benchmark | Variance +/- |
|---|---|---|---|---|
| United States of America | North America | 90.00% | 99.29% | -9.29% |
| China | Emerging Markets | 4.62% | 0.00% | 4.62% |
| Other | Other | 1.94% | 0.44% | 1.50% |
| United Kingdom | Europe | 1.62% | 0.00% | 1.62% |
| Canada | North America | 1.08% | 0.00% | 1.08% |
| Switzerland | Europe | 0.32% | 0.00% | 0.32% |
| Germany | Europe | 0.28% | 0.00% | 0.28% |
| France | Europe | 0.14% | 0.00% | 0.14% |
| Sweden | Europe | 0.00% | 0.13% | -0.13% |
| Singapore | Pacific | 0.00% | 0.00% | 0.00% |
| Brazil | Emerging Markets | 0.00% | 0.10% | -0.10% |
| Peru | Emerging Markets | 0.00% | 0.03% | -0.03% |
| Argentina | Emerging Markets | 0.00% | 0.00% | 0.00% |
| Panama | Emerging Markets | 0.00% | 0.00% | 0.00% |
| Israel | Middle East | 0.00% | 0.00% | 0.00% |
Holdings details
As at 31 Dec 2025
| Holding name | % of market value | Sector | Region | Market value | Shares |
|---|---|---|---|---|---|
| Micron Technology Inc | 4.56743% | Information Technology | US | €57,458,741.20 | 201,320 |
| Eli Lilly & Co | 4.47236% | Health Care | US | €56,262,722.04 | 52,353 |
| Xometry Inc | 3.42701% | Industrials | US | €43,112,181.80 | 724,940 |
| Flex Ltd | 2.69916% | Information Technology | US | €33,955,737.90 | 561,995 |
| Alphabet Inc | 2.49552% | Communication Services | US | €31,393,900.00 | 100,300 |
| Nextpower Inc | 2.43351% | Industrials | US | €30,613,851.29 | 351,439 |
| BeOne Medicines Ltd | 1.79952% | Health Care | US | €22,638,098.34 | 74,514 |
| Alibaba Group Holding Ltd | 1.78854% | Consumer Discretionary | US | €22,500,030.00 | 153,500 |
| GRAIL Inc | 1.72619% | Health Care | US | €21,715,638.03 | 253,717 |
| Rhythm Pharmaceuticals Inc | 1.63186% | Health Care | US | €20,528,987.52 | 191,788 |
Prices and distribution
Prices
NAV Price (EUR)
€2,079.03
Change
+€18.730.91% At closure 16 Mar 2026
NAV 52-week high
€2,233.46
At closure 17 Mar 2026
NAV 52-week low
€1,395.20
At closure 17 Mar 2026
NAV 52-week difference
€838.26
Change
+37.53% At closure 17 Mar 2026
Historical Prices
-
Inception date
04 Dec 2006
| Date | NAV (EUR) |
|---|---|
| 16 Mar 2026 | €2,079.0314 |
| 13 Mar 2026 | €2,060.3019 |
| 12 Mar 2026 | €2,044.3471 |
| 11 Mar 2026 | €2,089.1323 |
| 10 Mar 2026 | €2,068.5972 |
| 09 Mar 2026 | €2,081.2510 |
| 06 Mar 2026 | €2,051.9029 |
| 05 Mar 2026 | €2,089.7612 |
| 04 Mar 2026 | €2,113.7202 |
| 03 Mar 2026 | €2,107.4908 |
Distribution history
Distribution frequency
—
Historical performance 28 Feb 2026
0.52%
All dividends are reinvested for the "Accumulation" shares.
Purchase information
Currency
Base currency: EUR
Fund codes
- Bloomberg: VANGUOE
- Citi: HRG4
- ISIN: IE00B03HCV24
- MEX ID: VIUSOP
- SEDOL: B03HCV2